Department of Endocrinology, Bispebjerg Hospital, University of Copenhagen, DK-2400 Copenhagen NV, Denmark.
Center for Wound Healing, Bispebjerg Hospital, University of Copenhagen, DK-2400 Copenhagen NV, Denmark.
J Diabetes Complications. 2018 Dec;32(12):1141-1147. doi: 10.1016/j.jdiacomp.2018.09.013. Epub 2018 Sep 29.
Charcot foot is a rare but disabling complication to diabetic neuropathy, and can cause permanent, limb-threatening deformities. The aim of this study was to investigate a population of patients a Charcot foot on a case-by-case basis, in order to assess the consequences of an acute Charcot foot and its complications.
The study was conducted a retrospective study of patients admitted to the Copenhagen Wound Healing Center between 1996 and 2015 with the diagnosis of Charcot foot (DM14.6) and diabetes mellitus type 1 or 2 (DE10.X and DE11.X). Physical and electronic records were used, and compared to data from the Danish Diabetes Registry.
In total 392 patients were identified of which 173 were included. There were 26% with type 1 diabetes (initial HbA1c 81.7 ± 21.4 mmol/mol) and 74% with type 2 diabetes (initial HbA1c 66.5 ± 20.3 mmol/mol). Primary off-loading was with a removable walker in 95% of the cases (average off-loading time 8.3 months). The 5-year mortality was 14% with a mean survival time of 12.7 years. There was an association between lack of compliance and occurrence of foot complications, as well as between having a Charcot foot and leaving the workforce.
More patients had type 1 diabetes compared to the background population, and they had a higher HbA1c than the general population of diabetes patients. A total of 67% developed complications such as ulcers, while patients non-compliant to treatment did significantly worse than those being compliant. The 5-year mortality was low, 14%, and comparable to diabetes patients without Charcot foot.
夏科氏足是一种罕见但会导致残疾的糖尿病神经病变并发症,可导致永久性的、危及肢体的畸形。本研究的目的是对夏科氏足患者进行个案研究,以评估急性夏科氏足及其并发症的后果。
该研究是对 1996 年至 2015 年间在哥本哈根伤口愈合中心以夏科氏足(DM14.6)和 1 型或 2 型糖尿病(DE10.X 和 DE11.X)诊断入院的患者进行的回顾性研究。使用了病历和电子病历,并与丹麦糖尿病登记处的数据进行了比较。
共确定了 392 例患者,其中 173 例被纳入研究。其中 26%为 1 型糖尿病(初始 HbA1c 81.7±21.4mmol/mol),74%为 2 型糖尿病(初始 HbA1c 66.5±20.3mmol/mol)。95%的病例采用可移动助行器进行初始减压(平均减压时间 8.3 个月)。5 年死亡率为 14%,平均生存时间为 12.7 年。不遵医嘱与足部并发症的发生以及夏科氏足与离开工作岗位之间存在关联。
与背景人群相比,更多的患者患有 1 型糖尿病,且其 HbA1c 高于一般糖尿病患者。共有 67%的患者出现溃疡等并发症,而不遵医嘱治疗的患者明显比遵医嘱治疗的患者差。5 年死亡率为 14%,与无夏科氏足的糖尿病患者相当。